Purpose of Study: The Food and Drug Administration (FDA) gave approval of the Humanitarian Device Exemption (HDE) a Humanitarian use device for Medtronic Reclaim Therapy to Medtronic, Inc. (HDE# H050003). Medtronic Reclaim Deep Brain Stimulation (DBS) Therapy for Obsessive Compulsive Disorder (OCD) delivers electrical stimulation to areas in the brain to help control symptoms of treatment resistant OCD. The Medtronic Reclaim DBS Therapy is indicated for bilateral stimulation of a specific region of the brain (anterior limb of the internal capsule), in conjunction with OCD medications for treatment of chronic, severe, treatment resistant OCD in adult patients who have failed at least three selective serotonin reuptake inhibitor medications. DBS is used as an alternative to anterior capsulotomy (different type of surgery) that is indicated for this condition.

Principal Investigator: Milind Deogaonkar, MD 

Contact: Thomas Geist
Phone: 614-293-0580
Email: Thomas.geist@osumc.edu

Purpose of Study: This protocol is for a Humanitarian Device Exemption (HDE). The Food and Drug Administration (FDA) gave approval of the HDE of a Humanitarian Use Device (HUD) for Medronic Activa® Dystonia Therapy on April 13, 2003, to Medtronic, Inc. (HDE Number: H020007) and it was approved at Ohio State University on May 10, 2010. Medtronic Activa® Deep Brain Stimulation Dystonia Therapy delivers electrical stimulation to internal globus pallidus (GPi) or the subthalamic nucleus (STN) to aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia and cervical dystonia (torticollis) in patients seven years of age or above who have completed at least one year of other treatment before being considered a surgical candidate.

Description of Study: This is not a research study; it is an FDA requirement for humanitarian use of the deep brain stimulation device in treating a rare disease, dystonia.

Eligibility Criteria: Patients seven years of age or older with chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia and cervical dystonia (torticollis) who have completed at least one year of other treatment.

Principal Investigator: Vibhor Krishna, MD 

Contact: Thomas Geist
Phone: 614-293-0580
Email: Thomas.geist@osumc.edu

Purpose of Study: To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use. Also, to evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice.

Description of Study: The study is a prospective, multicenter, global registry of Boston Scientific neurostimulation systems for pain. The study treatment will consist of neurostimulation trial therapy with any commercially approved Boston Scientific Corporation neurostimulator for pain. Positive trials, subjects with a successful trial outcome, may progress to permanent implant of a neurostimulation system. Individualization of neurostimulation therapy for pain will be determined according to investigator discretion and site routine care, and in accordance with inclusion and exclusion criteria.

Eligibility Criteria: Men and women age 18 and older who are scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use, and have signed a valid, IRB/EC-approved informed consent form.

Status of Study: Recruiting

Principal Investigator: Milind Deogaonkar, MBBS

Contact: Thomas Geist
Phone: 614-293-0580
Email: Thomas.geist@osumc.edu

Sponsor: Boston Scientific Corporation

Purpose of Study: The purpose of this clinical study is to allow the investigation of the Neural Bridging System for participants with tetraplegia to assess if the investigational device can reanimate a paralyzed limb under voluntary control by the participant's thoughts.

Description of Study: This study plans to enroll participants who have been diagnosed with C4- C6 ASIA A spinal cord injuries (motor and sensory complete neurologic injuries), who are more than one year post injury, and who are neurologically stable.

Eligibility Criteria: Men and women age 21 to 89 who are tetraplegic (C4- C6 ASIA A), 12 months post injury and neurologically stable, willing to comply with all follow-up evaluations at the specified times, able to provide informed consent prior to enrollment in the study, fluent in English, and have a caregiver willing to participate in the study who will provide care for the surgical site.

Status of Study: Recruiting

Principal Investigator: Marcia Bockbrader, MD, PhD 

Contact: Thomas Geist
Phone: 614-293-0580
Email: Thomas.geist@osumc.edu